Upadacitinib (Rinvoq®). HTA ID: 23013

Assessment Status Rapid Review Complete
HTA ID 23013
Drug Upadacitinib
Brand Rinvoq®
Indication Upadacitinib (Rinvoq®) is indicated for the treatment of adult patients with moderately to severely active Crohn’s Disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Assessment Process
Rapid review commissioned 03/03/2023
Rapid review completed 21/04/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that upadacitinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement following confidential price negotiations. December 2023